Enterprise Value
-6.458M
Cash
19.08M
Avg Qtr Burn
-5.866M
Short % of Float
0.15%
Insider Ownership
22.18%
Institutional Own.
45.05%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Auxora™ Details Acute Pancreatitis | Phase 2b Data readout | |
GB-102 (Pan-VEGF inhibitor) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Phase 2 Update | |
GB-102 (Pan-VEGF inhibitor) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |